As a European full-service CRO, Accovion supports local and global projects of all types and phases for the pharmaceutical, biotechnology and medical device industries. Our premium services include study planning and management, clinical monitoring, pharmacovigilance (including post marketing safety), data management, biostatistics, statistical programming, medical writing and electronic publishing.
Accovion’s skilled professionals operate internationally and will benefit your projects by applying high-level expertise, state-of-the-art industry best practices and thorough knowledge of regulatory requirements.
Our vision is to be the preferred and trusted clinical development partner for global pharmaceutical, biotechnology and medical device companies.
We effectively deliver sophisticated clinical research services critical to development pathways without compromising quality or timelines.
Accovion is incorporated in Eschborn (Frankfurt), Germany.
- The management and senior staff of Accovion.
- HeidelbergCapital-Private Equity.
- Creathor Venture.
HeidelbergCapital is an independent, private equity funds group, specializing in secondary direct investments, e.g. the acquisition of shareholdings in companies previously held by private equity/venture capital funds or banks.
HeidelbergCapital was founded in mid 2007 by Prof. Dr. Martin Weiblen, former Managing Director of a multi-billion pound family office in London, UK and an advisor to several life science funds. The company is jointly managed with Dr. Clemens Doppler, former partner at 3i, a British private equity group. The New York-based private equity investor Auda has committed a total of 150 million US dollars for the first fund, HeidelbergCapital Private Equity Fund I.
The portfolio of HeidelbergCapital ranges from investments in later stage venture companies with a proven business model to established mid-sized operations. As an active partner, HeidelbergCapital supports the companies in strategic business decisions, but also provides, where appropriate, funding for further growth.
About HeidelbergCapital: http://www.heidelbergcapital.de/
Creathor is one of Germany's leading early-stage venture capital firms with a focus on investments in innovative technologies and business concepts in the sectors of life science, communications, IT, optics, and micro- and nanotechnologies.
Creathor's team, with its general partner and founder of former Technologieholding VC GmbH, Dr. Gert Köhler and partners Ingo Franz and Karlheinz Schmelig, has a successful track record of more than 20 years of investing in high-tech companies.
About Creathor Venture: www.creathor.de